Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)
Open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).
Chronic Lymphocytic Leukemia
DRUG: Navitoclax
Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety., The investigators will monitor each subject for clinical and lab evidence of adverse events on a routine basis through out the study. The investigators will question each subject regarding any adverse effects that they have experienced and record any events on the care report forms. All adverse events will be followed to a satisfactory clinical resolution., Adverse events occuring through the Final Visit (up to Week 52) will be reported|Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety., Physical exam, blood pressure, pulse, body temperature will be measured and recorded, Change from baseline through Final Visit (up to Week 52).|Safety: Clinical Lab Tests will be performed for each participant as a safety measure., Chemistry, hematology, urinalysis lab tests will be measured and recorded. All clinically significant values will be followed by the investigator to a satisfactory clinical resolution., Change from baseline through Final Visit (up to Week 52).
This is an open-label extension study of navitoclax in subjects with chronic lymphocytic leukemia (CLL).